Stock MARI MARINOMED BIOTECH AG
Add to a list
To use this feature you must be a member
Log inSign up

Company Marinomed Biotech AG

Equities

MARI

ATMARINOMED6

Pharmaceuticals

Market Closed - Wiener Boerse
Other stock markets
 06:13:56 03/05/2024 pm IST 		5-day change 1st Jan Change
16.7 EUR 0.00% Intraday chart for Marinomed Biotech AG -4.57% -42.81%
16/04 Transcript : Marinomed Biotech AG, 2023 Earnings Call, Apr 16, 2024
16/04 Marinomed Biotech AG Reports Earnings Results for the Full Year Ended December 31, 2023 CI

Business Summary

Marinomed Biotech AG, formerly known as Marinomed Biotechnologie GmbH is a Austria-based biopharmaceutical company. The company develops antiviral and immunological therapies such as nasal sprays using the respiratory disease antiviral technology platform, Marinosolv and the Carragelose platform. With the Marinosolv technology platform, it is possible to improve the effectiveness of poorly soluble active ingredients. This technology has the potential to change some therapies in the field of allergy and autoimmune diseases. The Carragelose platform is already used in six different products against viral infections of the respiratory tract. The company also offers products for the treatment of influenza, combination products for asthmatics, and others. The company also develops treatments for type I allergies and autoimmune diseases. The company is a spin-off from the University of Veterinary Medicine, Vienna.

Number of employees: 44

Sales per Business

EUR in Million2022Weight2023Weight Delta
Virology
99.3 %
11 99.3 % 9 99.3 % -18.60%
Other
0.7 %
0 0.7 % 0 0.7 % -12.87%

Sales per region

EUR in Million2022Weight2023Weight Delta
Other European Countries
50.9 %
7 60.8 % 5 50.9 % -31.82%
Non-European Countries
43.3 %
3 30.4 % 4 43.3 % +15.73%
Austria
5.8 %
1 8.8 % 1 5.8 % -45.68%

Managers

Managers TitleAgeSince
Andreas Grassauer CEO
 Chief Executive Officer 55 01/06/01
Eva Prieschl-Grassauer FOU
 Founder 56 01/06/01
Pascal Schmidt DFI
 Director of Finance/CFO 52 01/18/01
Helmut Baranyovszki COO
 Chief Operating Officer - 01/11/01
Renate Moser PRN
 Corporate Officer/Principal - 01/15/01

Members of the board

Members of the board TitleAgeSince
Simon Jules Nebel CHM
 Chairman 58 01/08/01
Brigitte Ederer BRD
 Director/Board Member 68 21/18/21
Elisabeth Lackner BRD
 Director/Board Member - 15/22/15
Ulrich Kinzel BRD
 Director/Board Member 60 15/22/15
Eva Hofstädter-Thalmann BRD
 Director/Board Member - 20/23/20

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 1,540,530 1,002,892 ( 65.10 %) 0 65.10 %

Shareholders

NameEquities%Valuation
Erste Asset Management GmbH
8.686 %
133,350 8.686 % 3 M €
Matejka & Partner Asset Management GmbH
4.472 %
68,659 4.472 % 2 M €
SK Vermögensverwaltung GmbH
2.866 %
44,000 2.866 % 1 M €
3 Banken-Generali Investment-Gesellschaft mbH
2.254 %
34,600 2.254 % 818 359 €
Conseq Investment Management AS
1.674 %
25,700 1.674 % 607 856 €
Acropora Beteiligungs GmbH
0.8018 %
12,310 0.8018 % 291 156 €
Sparkasse Oberösterreich Kapitalanlagegesellschaft m.bH.
0.7458 %
11,450 0.7458 % 270 815 €
amandea Vermögensverwaltung AG
0.2098 %
3,221 0.2098 % 76 183 €
Gutmann KAG
0.1400 %
2,150 0.1400 % 50 852 €
Fund Development & Advisory AG
0.1075 %
1,650 0.1075 % 39 026 €

Company contact information

Marinomed Biotech AG

Hovengasse 25

2100, Korneuburg

+43 2262 90300

http://www.marinomed.com
address Marinomed Biotech AG(MARI)

Sector

Healthcare
Pharmaceuticals & Medical Research
Pharmaceuticals
Pharmaceuticals
Biopharmaceuticals

Sales per Business

Sales per region

Ratings for Marinomed Biotech AG

Trading Rating
Investor Rating
ESG Refinitiv
More Ratings

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
16.7 EUR
Average target price
63 EUR
Spread / Average Target
+277.25%
Consensus

EPS Revisions

Estimates Revisions

Annual profits - Rate of surprise

Company calendar

Sector Biopharmaceuticals

1st Jan change Capi.
MARINOMED BIOTECH AG Stock Marinomed Biotech AG
-42.81% 27.71M
CSL LIMITED Stock CSL Limited
-3.79% 88.14B
SAMSUNG BIOLOGICS CO.,LTD. Stock Samsung Biologics Co.,Ltd.
+1.45% 40.51B
BIOGEN INC. Stock Biogen Inc.
-15.94% 31.67B
UCB Stock UCB
+52.66% 24.62B
BIOMARIN PHARMACEUTICAL INC. Stock BioMarin Pharmaceutical Inc.
-14.50% 15.65B
BEIJING WANTAI BIOLOGICAL PHARMACY ENTERPRISE CO., LTD. Stock Beijing Wantai Biological Pharmacy Enterprise Co., Ltd.
-9.12% 11.97B
INCYTE CORPORATION Stock Incyte Corporation
-14.38% 12.07B
CHONGQING ZHIFEI BIOLOGICAL PRODUCTS CO., LTD. Stock Chongqing Zhifei Biological Products Co., Ltd.
-42.56% 11.61B
SWEDISH ORPHAN BIOVITRUM AB Stock Swedish Orphan Biovitrum AB
+4.87% 8.81B
Biopharmaceuticals
  1. Stock Market
  2. Equities
  3. MARI Stock
  4. Company Marinomed Biotech AG